NCT03010982View on ClinicalTrials.gov

Open-Label, Multi-Center, Two-Part, Ph1 Study to Characterize the PKs of an Intravenous Micro-Dose of [14C]-Tazemetostat (EPZ 6438) and the ADME of an Oral [14C]-Labeled Dose of Tazemetostat in Subjects With B-Cell Lymphomas or Adv Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

June 20, 2018

Primary Completion Date

January 8, 2019

Study Completion Date

January 8, 2019

Conditions
Diffuse Large B Cell LymphomaPrimary Mediastinal LymphomaMantle-Cell LymphomaFollicular LymphomaMarginal Zone LymphomaAdvanced Solid Tumors
Interventions
DRUG

Tazemetostat and [14C] Tazemetostat

Tazemetostat is a selective oral small molecule inhibitor of EZH2.

Trial Locations (2)

Unknown

The Clatterbridge Cancer Centre NHS Foundation Trust, Bebington

L7 8XP

Royal Liverpool and Broadgreen University Hospital Trust, Liverpool

Sponsors

Lead Sponsor

Epizyme, Inc.
All Listed Sponsors
lead

Epizyme, Inc.

INDUSTRY